Better Health for All

Alumis is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and neuroinflammatory diseases. Its lead product candidate, envudeucitinib, demonstrated significant positive health benefits in Phase 3 trials for moderate-to-severe plaque psoriasis, with approximately 65% of patients achieving PASI 90 and over 40% achieving PASI 100 at Week 24.

The company's entire business model is dedicated to developing these health-improving therapies. As a clinical-stage company, Alumis has no products with significant negative health impacts. Envudeucitinib also showed a favorable safety and tolerability profile in Phase 3 trials, with most treatment-emergent adverse events being mild to moderate, transient, and no new safety signals observed. The company's clinical trials are described as randomized, double-blind, placebo-controlled, and multi-center, following protocols to monitor and safeguard patient experiences. Alumis has an Expanded Access Policy (EAP) for investigational drugs for patients with serious or immediately life-threatening illnesses who are ineligible for trials, but currently does not offer expanded access. The company's R&D expenses were $108.8 million for Q2 2025, up from $48.6 million in Q2 2024. Alumis provides patient resources for expert guidance, support, and tools. However, the company's press release contains forward-looking statements with cautions about differing actual results due to various risks and uncertainties detailed in SEC filings. The company mentions that immune-mediated diseases can bring daily emotional challenges and that plaque psoriasis and thyroid eye disease can cause emotional distress, but there is no evidence of practical support or resources for mental health.

Fair Pay & Worker Respect

No specific, concrete data points were found across the provided articles for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce was not explicitly stated.

While a severance plan includes company-paid COBRA health insurance premiums for terminated employees, this does not provide a percentage of the entire workforce with employer-funded health insurance.

Honest & Fair Business

The provided article from investors.alumis.com confirms the existence of several governance documents, including a Code of Business Conduct and Ethics, Corporate Governance Guidelines, a Whistleblower and Complaint Policy, and various Committee Charters.

However, the article explicitly states that it contains no quantitative data, regulatory actions, violations, fines, certifications, awards, recognitions, or comparisons to industry benchmarks. Consequently, there is no specific, concrete evidence to assess Alumis Inc. against any of the defined KPIs for the 'Honest & Fair Business' value, as all rubric tiers require specific metrics, implementation details, or performance outcomes rather than just the presence of a policy.

Kind to Animals

No specific data or actions related to Alumis Inc.'s performance on animal welfare, animal testing, ethical sourcing, or conservation initiatives were found in the provided articles.

The available information primarily focuses on the company's financial status and IPO details , or discusses the FDA's plans regarding animal testing , which is not directly attributable to Alumis Inc.

No War, No Weapons

The provided articles, including company investor reports, a code of business conduct, and general information, do not contain specific, concrete data points or explicit statements regarding Alumis Inc.'s involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other activities directly related to war or weapons.

The company is described as a clinical-stage biopharmaceutical company focused on autoimmune diseases. While this business model suggests a lack of involvement in the defense sector, the articles do not explicitly state a zero-exposure policy or provide quantitative data for any of the KPIs in the 'No War, No Weapons' rubric. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

The provided articles focus exclusively on Alumis Inc.'s drug development pipeline, clinical programs, financial results, and corporate updates, including a merger agreement. Each article explicitly states the absence of any data related to the company's environmental, social, or governance (ESG) performance or specific planet-friendly business metrics.

Therefore, no evidence is available to assess the company against any of the 'Planet-Friendly Business' KPIs.

Safe & Smart Tech

Alumis Inc. states compliance with data privacy and security obligations, as well as FDA and healthcare fraud and abuse laws and regulations.

The company's privacy policy was last updated on January 6th, 2022. Alumis Inc. also states it does not knowingly collect Personal Data from children under the age of 13. The company acknowledges risks related to employee use of generative AI technologies and personnel misconduct or error, and mentions taking steps designed to anticipate, detect, and remediate threats and vulnerabilities. It relies on third-party service providers for encryption and authentication technology.

Zero Waste & Sustainable Products

No sustainability data or specific information related to waste management, product design, or packaging sustainability for Alumis Inc. (ALMS.US) is available in the provided articles.

The articles explicitly state that sustainability data is unavailable, preventing any assessment against the 'Zero Waste & Sustainable Products' value for any KPI.